5:27 PM
 | 
Oct 02, 2012
 |  BC Extra  |  Company News

Ablynx, Merck in Nanobodies deal

Ablynx N.V. (Euronext:ABLX) partnered with Merck & Co. Inc. (NYSE:MRK) to develop and commercialize Ablynx's Nanobodies targeting an undisclosed voltage-gated ion channel. The deal includes...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >